title: Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension.
abstract: To assess the effects of pharmacological interruption of the renin-angiotensin system on the fibrinolysis, tissue plasminogen activator antigen (t-PA), plasminogen activator inhibitor-1 antigens (PAI-1) and neurohormones, such as plasma renin activity, norepinephrine, angiotensin II (AII) and IV (AIV) concentrations, were measured in 60 hypertensives. Among them, 48 patients were divided into two groups (25 with 10-20 mg quinapril and 23 with 50-100 mg losartan) who received the drug for 6 months. AII had a weak positive correlation with free PAI-I (n = 60, r = 0.26, p < 0.05) whereas AIV had a strong positive correlation with free PAI-I (n = 60, r = 0.57, p < 0.0001). In both treatment groups, blood pressures were significantly reduced to similar levels after drug treatment. While plasma renin activity increased significantly in both groups after drug treatment, only the losartan group showed significant increases in AII and AIV concentrations. In the quinapril group, there was a significant change in t-PA (p < 0.001) without changes in PAI-1. In the losartan group, free PAI-I and total PAI-I (p < 0.05 for free PAI-I and p < 0.04 for total PAI-I) were significantly increased without a change in t-PA. Thus, quinapril enhanced fibrinolysis but losartan attenuated it. These unique effects of each drug on the fibrinolytic system appear to be associated with changes in AII and AIV concentrations.
authors.affiliation: Department of Nuclear Medicine, Shizuoka General Hospital, Shizuoka, Japan. k.sakata@scchr.jp
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Sakata
authors.forename: Roberts
authors.initials: R
authors.lastname: Pawlak
authors.forename: Tetumei
authors.initials: T
authors.lastname: Urano
authors.forename: Akikazu
authors.initials: A
authors.lastname: Takada
mesh_terms: D000328:Adult; D000804:Angiotensin II / Q000031:analogs & derivatives* / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D007546:Isoquinolines / Q000008:administration & dosage / Q000494:pharmacology; D019808:Losartan / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D000077583:Quinapril; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*; D044005:Tetrahydroisoquinolines; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000097:blood
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007546:Isoquinolines; D017395:Plasminogen Activator Inhibitor 1; D044005:Tetrahydroisoquinolines; D000804:Angiotensin II; C012877:angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-; D010959:Tissue Plasminogen Activator; D019808:Losartan; D000077583:Quinapril